Back

Low utilization of GLP-1RAs and SGLT2i in high-risk cardiovascular patients with diabetes: nationwide insights from myocardial Infarction and stroke survivors

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (4) - Secondary prevention Secondary Prevention ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Michal Vrablik

Charles University of Prague, Prague (Czechia)

10 More presentations in this session

Presentation thumbnail
Discussant - Secondary prevention
Presentation thumbnail
Trajectories of adherence to secondary prevention pharmacotherapy after coronary angiography: a retrospective population-based study
Doctor L. Heitmann (Reykjavik, IS)
Abstract Slides Video
Presentation thumbnail
Evaluation of diagnostic accuracy of extreme cardiovascular risk definitions in acute coronary syndrome patients
Doctor A. Maloberti (Milan, IT)
Abstract Slides Video
Presentation thumbnail
CVDPREVENT- the national audit of cardiovascular disease prevention in primary care in England driving quality improvement
Mrs L. Corteville (Manchester, GB)
Abstract Slides Video
Presentation thumbnail
GLP-1 receptor agonists as an opportunity for patients with atherosclerotic cardiovascular disease as well as obesity in Germany
Doctor V. Oettinger (Freiburg, DE)
Abstract

Access the full session

Session thumbnail
New perspectives in cardiology (4) - Secondary prevention

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
GLP-1 receptor agonists and SGLT2-inhibitors in patients with diabetes and ischaemic heart disease in primary care
thumbnail
Congress Presentation
Use of cardioprotective glucose lowering therapy before and after myocardial infarction among patients with type-2 diabetes: a nationwide registry study
thumbnail
Congress Presentation
Real-life use of novel glucose lowering agents after acute myocardial infarction and stable coronary artery disease in patients with diabetes - experience from national use in the SWEDEHEART-registry

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources